Advertisement

Topics

Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy

11:26 EST 14 Nov 2017 | Topix

A unit of healthcare conglomerate Johnson & Johnson has dropped a lawsuit it filed to block a copy of its rheumatoid arthritis drug Remicade produced by South Korea's Samsung Bioepis Co Ltd from being sold in the United States. Janssen Biotech Inc, in a document to the U.S. District Court of New Jersey dated Friday and seen by Reuters, voluntarily dismissed its suit to block Samsung Bioepis' biosimilar of Remicade from sale.

Original Article: Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy

NEXT ARTICLE

More From BioPortfolio on "Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy"

Advertisement
Quick Search
Advertisement
Advertisement